US regulatory nod for Zydus drug to treat dementia
We have received final approval from USFDA to market Memantine Hydrochloride tablets: Zydus12-07-2017
12-07-2017
Shareholding for the Period Ended June 30, 2017
Zydus Wellness Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2017. For more details, kindly Click here11-07-2017
Status Of Complaints As On June 30, 2017
Please find attached herewith the complaint status as on June 30, 2017.11-07-2017
Zydus begins Phase-II trials for its new anaemia drug Zyan1
Developed drug, an oral molecule, is the latest new chemical entity from the firm's pipeline05-07-2017
USFDA nod for Zydus skin drug
Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA, has received final approval from the USFDA to market Nystatin Topical Powder USP, 100,000 units per gram. The drug will be...11-06-2017
Zydus' Nesher Pharma gets US FDA nod for antifungal drug
The drug will be produced at Nesher Pharmaceuticals manufacturing facility in USA10-06-2017
Fixes Book Closure for AGM
Zydus Wellness Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from July 31, 2017 to August 11, 2017 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on August 11, 2017.30-05-2017
Zydus Wellness Q4 net up 9% at Rs 30 crore
The company had posted a net profit of Rs 27.73 crore in the same period a year ago27-05-2017
Outcome of Board Meeting
The Board of Directors at their meeting held today have confirmed the interim dividend declared and paid by the Board of Directors, as the final dividend for the Financial Year 20162017. No final dividend is proposed to be declared at the ensuing Annual General Meeting.27-05-2017
Outcome of Board Meeting
Pursuant to the SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016, we hereby give a declaration that the Statutory AuditorsM/s. Dhirubhai Shah & Doshi [Firm Registration No. 102511W], Chartered Accountants have submitted their Audit Reports for the year ended on March 31, 2017 with an unmodified opinion.27-05-2017